Biocompatibility and paclitaxel/cisplatin dual-loading of nanotubes prepared from poly(ethylene glycol)-polylactide-poly(ethylene glycol) triblock copolymers for combination cancer therapy

Shen, Xin; Wang, Yuandou; Xi, Laishun; Su, Feng; Li, Suming

doi:10.1016/j.jsps.2019.08.005

Cited by 8 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[47,48] Among those, multidrug resistance (MDR) is the greatest obstacle in using chemotherapeutic agents, which diminishes the efficacy of mono-chemotherapeutic molecules to eradicate cancer development. [49] Due to these limitations, combinatorial strategies have developed. Co-delivery of chemotherapeutic agents has many advantages those are clearly represented in Figure 1, including synergistic effects and the capability to overcome MDR.…”

Section: Why Combination Therapy?mentioning

confidence: 99%

See 1 more Smart Citation

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

siRNA interference is a conserved cellular gene silencing mechanism and a viable technique for human disease intervention, including cancer. This method has significant potential benefits over currently available treatments. The limitations of using siRNA‐based systems are the lack of specificity, high chance of degradation, toxicity, and ineffective cellular uptake. Combination therapy using natural compounds possesses higher therapeutical value with siRNA. Various natural compounds are used in cancer treatments such as paclitaxel, ursolic acid, hypericin, etoposide, etc due to their diverse bioactivities. In this review, the codelivery of natural compounds/siRNA using nanovehicles is highlighted.

show abstract

Section: Why Combination Therapy?mentioning

confidence: 99%

“…Among those, multidrug resistance (MDR) is the greatest obstacle in using chemotherapeutic agents, which diminishes the efficacy of mono‐chemotherapeutic molecules to eradicate cancer development [49] . Due to these limitations, combinatorial strategies have developed.…”

Section: Introductionmentioning

confidence: 99%

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Particularly, miR is implicated in tumor resistance. For instance, cisplatin is a potential chemotherapeutic agent with the ability of inhibiting the proliferation and viability of various cancers [ 206 ]. In ovarian cancer, it has been reported that miR-137 reduces the expression of MCL1 to sensitize tumor cells into cisplatin-induced apoptosis [ 207 ].…”

Section: Micrornas Zeb and Their Role In Tumor Resistancementioning

confidence: 99%

MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Molecular signaling pathways involved in cancer have been intensively studied due to their crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding homeobox-1 (ZEB1) and -2 (ZEB2) are molecules that play vital roles in signaling pathways to ensure the survival of tumor cells, particularly through enhancing cell proliferation, promoting cell migration and invasion, and triggering drug resistance. Importantly, ZEB proteins are regulated by microRNAs (miRs). In this review, we demonstrate the impact that miRs have on cancer therapy, through their targeting of ZEB proteins. MiRs are able to act as onco-suppressor factors and inhibit the malignancy of tumor cells through ZEB1/2 down-regulation. This can lead to an inhibition of epithelial-mesenchymal transition (EMT) mechanism, therefore reducing metastasis. Additionally, miRs are able to inhibit ZEB1/2-mediated drug resistance and immunosuppression. Additionally, we explore the upstream modulators of miRs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), as these regulators can influence the inhibitory effect of miRs on ZEB proteins and cancer progression.

show abstract

“…These difficulties have spurred scientists toward developing co-delivery strategies for anticancer therapy. Combination cancer treatment indeed has significant appeal owing to its many advantages over monodelivery therapeutics, including improved efficacy by synergistic effects and overcoming drug resistance. − In this regard, various siRNA and natural compounds co-delivery vehicles have been developed to achieve more effective therapy than conventional monodelivery . Natural compounds, because of their biobased origin, have attracted more attention than synthetic drugs .…”

Section: Introductionmentioning

confidence: 99%

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, codelivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.

show abstract

Biocompatibility and paclitaxel/cisplatin dual-loading of nanotubes prepared from poly(ethylene glycol)-polylactide-poly(ethylene glycol) triblock copolymers for combination cancer therapy

Cited by 8 publications

References 51 publications

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

Contact Info

Product

Resources

About